Author:
O’Hearn Katie,Menon Kusum,Weiler Hope A.,Amrein Karin,Fergusson Dean,Gunz Anna,Bustos Raul,Campos Roberto,Catalan Valentina,Roedl Siegfried,Tsampalieros Anne,Barrowman Nick,Geier Pavel,Henderson Matthew,Khamessan Ali,Lawson Margaret L.,McIntyre Lauralyn,Redpath Stephanie,Jones Glenville,Kaufmann Martin,McNally Dayre,
Abstract
Abstract
Background
Vitamin D deficiency (VDD) is highly prevalent in the pediatric intensive care unit (ICU) and associated with worse clinical course. Trials in adult ICU demonstrate rapid restoration of vitamin D status using an enteral loading dose is safe and may improve outcomes. There have been no published trials of rapid normalization of VDD in the pediatric ICU.
Methods
We conducted a multicenter placebo-controlled phase II pilot feasibility randomized clinical trial from 2016 to 2017. We randomized 67 critically ill children with VDD from ICUs in Canada, Chile and Austria using a 2:1 randomization ratio to receive a loading dose of enteral cholecalciferol (10,000 IU/kg, maximum of 400,000 IU) or placebo. Participants, care givers, and outcomes assessors were blinded. The primary objective was to determine whether the loading dose normalized vitamin D status (25(OH)D > 75 nmol/L). Secondary objectives were to evaluate for adverse events and assess the feasibility of a phase III trial.
Results
Of 67 randomized participants, one was withdrawn and seven received more than one dose of cholecalciferol before the protocol was amended to a single loading dose, leaving 59 participants in the primary analyses (40 treatment, 19 placebo). Thirty-one/38 (81.6%) participants in the treatment arm achieved a plasma 25(OH)D concentration > 75 nmol/L versus 1/18 (5.6%) the placebo arm. The mean 25(OH)D concentration in the treatment arm was 125.9 nmol/L (SD 63.4). There was no evidence of vitamin D toxicity and no major drug or safety protocol violations. The accrual rate was 3.4 patients/month, supporting feasibility of a larger trial. A day 7 blood sample was collected for 84% of patients. A survey administered to 40 participating families showed that health-related quality of life (HRQL) was the most important outcome for families for the main trial (30, 75%).
Conclusions
A single 10,000 IU/kg dose can rapidly and safely normalize plasma 25(OH)D concentrations in critically ill children with VDD, but with significant variability in 25(OH)D concentrations. We established that a phase III multicentre trial is feasible. Using an outcome collected after hospital discharge (HRQL) will require strategies to minimize loss-to-follow-up.
Trial Registration.
Clinicaltrials.gov NCT02452762 Registered 25/05/2015.
Funder
Canadian Institutes of Health Research
AHSC AFP Innovation Fund
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference91 articles.
1. Lalgudi Ganesan S, Garros D, Foster J, Di Genova T, Fontela PS, Murthy S. Pediatric critical care capacity in Canada: a national cross-sectional study. medRxiv. 2022:2022.12.07.22283061.
2. Pollack MM, Holubkov R, Funai T, Berger JT, Clark AE, Meert K, et al. Simultaneous Prediction of New Morbidity, Mortality, and Survival Without New Morbidity From Pediatric Intensive Care: A New Paradigm for Outcomes Assessment. Crit Care Med. 2015;43(8):1699–709.
3. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003;362(9379):192–7.
4. Muranjan MN, Birajdar SB, Shah HR, Sundaraman P, Tullu MS. Psychological consequences in pediatric intensive care unit survivors: the neglected outcome. Indian Pediatr. 2008;45(2):99–103.
5. Ricci MF, Andersen JC, Joffe AR, Watt MJ, Moez EK, Dinu IA, et al. Chronic Neuromotor Disability After Complex Cardiac Surgery in Early Life. Pediatrics. 2015;136(4):e922–33.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献